The surveillance recommendations for individuals with PALB2 gene mutations focus primarily on early detection and prevention of breast and pancreatic cancers and are similar to those for BRCA1/2 mutation carriers, given the significantly increased risk associated with these mutations (Table 1 and 2) (8, 26). This evidence concerns the gene PALB2 and familial pancreatic carcinoma.